August 30, 2014 11:40 PM ET

Biotechnology

Company Overview of Hepregen Corporation

Company Overview

Hepregen Corporation develops bio-engineered solutions for drug discovery and development applications in the pharmaceutical industry. The company develops and commercializes HepatoPac, a bio-engineered micro-liver platform for use in a range of applications, including metabolite identification, toxicity screening, clearance, drug-drug interactions, transporter involvement, in silico models, toxicogenomics, and disease modeling applications in humans; and HepatoMune, a micro-liver assay kit to predict toxicologic outcomes caused by the interaction of drugs and/or biologics with an inflamed liver. Its solutions are also used in cosmetic and environmental testing industries. The company was fo...

200 Boston Avenue

Suite 1500

Medford, MA 02155

United States

Founded in 2007

Phone:

781-391-0205

Fax:

781-391-0315

Key Executives for Hepregen Corporation

Chief Executive Officer and Director
Age: 67
Co-Founder and Director of Research
Chief Financial Officer and Vice President of Finance and Administration
Age: 60
Vice President of Operations
Compensation as of Fiscal Year 2014.

Hepregen Corporation Key Developments

Hepregen Corporation Launches First Rat Hepatopac Assay Kit to Evaluate Hepatotoxicity in the Laboratory

Hepregen Corporation announced the commercial launch of the company's first rat HepatoPac kit designed specifically for toxicology applications. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned rat liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates mirror the behavior of liver cells in live animals, enabling scientists to generate data that can be useful for prediction of toxic responses to chemical agents (including drug candidates) and improve design of preclinical experiments for drug development. The application-irected kit also provides a tool for the study of the mechanisms leading to such responses. The kit is available with rat liver cells derived from either Sprague-Dawley or Wistar-Han rats, two strains of animal commonly used by pharmaceutical, cosmetic and chemical companies for assessing the potential toxicity of chemical compounds in product development.

Hepregen Launches Human HepatoMune(TM) Assay Kit to Evaluate Inflammation-Mediated Hepatotoxicity in the Laboratory

Hepregen Corporation announced the commercial launch of the company's first human HepatoMune(TM) micro-liver assay kit. The kit is designed specifically to predict toxicologic outcomes caused by the interaction of drugs and/or biologics with an inflamed liver. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells (hepatocytes) co-cultured with stromal cells to which fully functional human liver immune cells (Küpffer cells) are added. Like their macrophage counterparts in the circulation, Küpffer cells located in the liver can engulf foreign invaders and macromolecules such as proteins. Moreover, these cells can also be stimulated to release cytokines as a result of interactions with inflammation-inducing agents. Cytokines, which are cell-signaling proteins of the immune system, can interact with small chemical entities or their metabolites, provoking damage to hepatocytes. The Küpffer cells and hepatocytes in HepatoMune(TM) plates together mirror the interactive behavior of these two cell types in the body. The human HepatoMune(TM) kit provides a tool to researchers that can be used in the laboratory to generate data useful for: (1) identifying potential inflammation-mediated liver toxicity resulting from exposure to chemical or biological agents, (2) studying mechanisms of toxicity, and (3) evaluating the potential for drug-drug and drug-biologic interactions that can be harmful to liver tissue. Consequently, these data can be useful for prediction of toxic responses to chemical agents, including drug candidates and biological agents such as monoclonal antibodies or recombinant proteins used for therapy.

Hepregen Corporation Announces Commercial Launch of HepatoPac Kit Designed Specifically for Toxicology Applications

On March 24, 2014, at the Society of Toxicology's 53rd Annual Meeting, Hepregen Corporation announced the commercial launch of the company's first HepatoPac kit designed specifically for toxicology applications. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates mirror the behavior of liver cells in the body, enabling scientists to generate data that can be useful for prediction of toxic responses to chemical agents, including drug candidates. The application-directed platform also provides a tool for the study of the mechanisms leading to such responses.

Similar Private Companies By Industry

Company Name Region
Cellanyx Diagnostics, Inc. United States
IMI International Medical Innovations, Inc. United States
Trius Therapeutics, Inc. United States
Phylogix, Inc. United States
Targeted Diagnostics & Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hepregen Corporation, please visit www.hepregen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.